Hemmie Chang

Partner, Chair, Licensing & Strategic Alliances Practice - Boston

Bio photo for Hemmie Chang
Download Media Photo

Contact Information

As Chair of Foley Hoag's Licensing & Strategic Alliances Practice Group, partner Hemmie Chang regularly handles high profile intellectual property matters. Clients routinely benefit from Hemmie's strategic business perspective and legal acumen from her two-plus decades of experience within the life sciences, energy and cleantech and technology sectors. She advises both established and emerging companies on a wide variety of licensing matters, from development to marketing deals - all of which involve a broad range of intellectual property assets, from brand names to copyright, patents to trade secrets. Hemmie is also very active within the firm’s Business Department and Life Science and Technology practice groups.

Most recently, Hemmie negotiated collaborations for Zosano's transdermal delivery technology with Novo Nordisk and Living Proof's Strateris™ platform with Valeant Pharmaceuticals, represented Metamark Genetics in its $365 million collaboration with Janssen Pharmaceuticals, and advised on early stage research agreements with AstraZeneca, GSK, Medtronic, Merck and Sanofi. Hemmie is often sought out for comment as an expert on licensing and strategic alliance topics. She was recently invited to write "Partnering Prenuptials: Translating Priorities into Deal Terms" for The Burrill Report (June 2013), and has been quoted in the World Intellectual Property Review and The Pink Sheet, "In 2012, Buyer’s Market Made Alliances Rarer," January 7, 2013.

Education:

  • Harvard Law School, J.D.
  • Princeton University Woodrow Wilson School of International and Public Affairs, A.B.

Representative Experience

Represents clients in collaboration and licensing transactions and investments with major pharmaceutical and emerging high-growth companies, and successfully counsels clients on investments, mergers and acquisitions and financings in energy and renewables (solar, wind) and other projects, including:

  • Represented Applied Genetic Technologies (NASDAQ: AGTC) in its recent initial public offering of common stock raising approximately US $52 million after completion of a $37.5 million Series B financing with Alta Partners, S.R. One, InterWest Partners, MedImmune Ventures and Intersouth Partners.
  • Advised Good Start Genetics, Inc. in a collaboration agreement with PerkinElmer, Inc.
  • Represented Zosano Pharma, Inc. in its agreement with Novo Nordisk A/S to develop a new transdermal presentation of semaglutide.
  • Advised Living Proof, Inc., in its global venture with Valeant Pharmaceuticals International, Inc. to develop, distribute and commercialize products for aesthetic dermatology.
  • Assisted NextCODE Health with securing an exclusive license for sequence-based clinical diagnostic applications using technology developed by deCODE genetics, and also with securing $15 million in Series A financing from Polaris Partners and ARCH Venture Partners.
  • Advised High Performance Optics in its exclusive and global license agreement with Essilor.
  • Successfully advised Metamark Genetics-Janssen Biotech in an early stage discovery collaboration deal in cancer (up to $365 million in milestone payments).
  • Worked on the development and supply agreement of robotic surgical instruments for the U.S. subsidiary of a major Japanese conglomerate.
  • Crafted an early stage discovery and equity investment biofuels deal with a major European partner.
  • Represented Arisaph Pharmaceuticals in a major reset of royalty and other payments to monetize $26.25 million in upfront and ongoing payments from Royalty Pharma.
  • Represented Bioneer, a Korean public biotech, in a research collaboration with Sanofi.
  • Worked on the Translational Therapeutics Inc.-Clavis Pharma, Inc. oncology candidate in-license (named BioWorld International Deal of the Week; May 2011).
  • Licenses in settlement of multimillion dollar litigation on behalf of Biogen Idec, Becton-Dickinson, and GI Dynamics.
  • Spinoff of assets (e.g. Bayer Healthcare oncology assets programs, IntElect Medical deep brain stimulation technology from The Cleveland Clinic).
  • Advised on early stage development deals for NYU spinoff with Medtronic, NuVasive and Stryker, agreements with Life Technologies and Illumina and option and development deals with GlaxoSmithKline, Sanofi and research collaboration with AstraZeneca.
  • Advise on numerous academic licenses from Harvard, MIT, Whitehead Institute, Johns Hopkins and UCSF.

Professional Experience

  • Biotechnology Industry Organization, Moderator and Speaker
  • Licensing Executives Society, Moderator and Speaker
  • Massachusetts Biotechnology Council, Faculty
  • Massachusetts Continuing Legal Education, Faculty

Honors

  • Listed in New England Super Lawyers Magazine (2013)
  • Articles Editor, Harvard Law Review
  • Phi Beta Kappa, Woodrow Wilson School of Public and International Affairs

Involvement

  • South Cove Manor, Nursing & Rehabilitation Center, Inc. and South Cove Nursing Facilities Foundation, Board Member
  • Franklin Square House Foundation, Board Member
  • National Asian Pacific American Bar Association (NAPABA), Member
  • The Commonwealth of Massachusetts Advisory Group on Undergraduate Education, Member
  • Asian American Lawyers Association of Massachusetts, Founding Director
  • Asian Task Force Against Domestic Violence, Founding Director
Add to Bio Folder

Download Bio

Bar Admissions

  • Massachusetts
  • District of Columbia
  • Practising Solicitor England Wales